News|Articles|November 16, 2026

FDA Approves Pertuzumab Biosimilar Pebrilzo for HER2+ Breast Cancer

Author(s)By ONN Staff
Fact checked by: Alex Biese

Pertuzumab-qcay is the second FDA-approved biosimilar to Perjeta, but a settlement with Genentech delays its US launch until Q3 2028.

The FDA has approved pertuzumab-qcay (Pebrilzo), a biosimilar to pertuzumab (Perjeta), for adults with HER2-positive metastatic and early breast cancer, according to a November 16, 2026, announcement from Biocon Biologics.1 Under a global settlement and license agreement with Genentech, the earliest licensed US launch date for the biosimilar is the third quarter of calendar year 2028, so the product is not expected in US practice until 2028.

Pertuzumab-qcay is a monoclonal antibody that blocks HER2 receptors on cancer cells.1 It is the second pertuzumab biosimilar approved in the United States, following pertuzumab-dpzb (Poherdy), which the FDA approved in November 2025 as the first biosimilar and first interchangeable biosimilar to Perjeta.2,3

Which patients is pertuzumab-qcay approved for?

The approval mirrors the indications of the reference product.1 Pertuzumab-qcay is indicated:

  • In combination with trastuzumab and docetaxel for adults with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease
  • In combination with trastuzumab and chemotherapy as neoadjuvant treatment of adults with HER2-positive, locally advanced, inflammatory, or early-stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer
  • In combination with trastuzumab and chemotherapy as adjuvant treatment of adults with HER2-positive early breast cancer at high risk of recurrence

The release did not state whether the FDA designated pertuzumab-qcay as interchangeable with Perjeta.1

What data supported the biosimilar approval?

According to Biocon, the approval was based on structural and functional analytical characterization, analytical similarity, and comparative clinical pharmacokinetic data, which the company said confirmed that pertuzumab-qcay is highly similar to Perjeta with no clinically meaningful differences in quality, safety, efficacy, or immunogenicity.1 The release did not name a comparative clinical efficacy trial or report patient numbers or end point results.1

What safety information should nurses know about?

Like the reference product, pertuzumab-qcay carries a boxed warning for left ventricular dysfunction and embryo-fetal toxicity.1 The label language states that the agent "can cause subclinical and clinical cardiac failure manifesting as decreased LVEF and CHF," and directs clinicians to "evaluate cardiac function prior to and during treatment."1 Treatment should be discontinued for a confirmed clinically significant decrease in left ventricular function.1

Exposure during pregnancy can cause embryo-fetal death and birth defects, and patients should be advised of these risks and the need for effective contraception.1 Pertuzumab can also cause serious infusion reactions, including fatal events; patients should be observed closely for 60 minutes after the first infusion and for 30 minutes after subsequent infusions.1 Hypersensitivity reactions and anaphylaxis are also listed, and the product is contraindicated in patients with known hypersensitivity to pertuzumab or its excipients.1

The most common adverse reactions (>30%) vary by regimen. In metastatic disease with trastuzumab and docetaxel, they were diarrhea, alopecia, neutropenia, nausea, fatigue, rash, and peripheral neuropathy.1

What did Biocon say about the approval?

"For patients diagnosed with HER2-positive breast cancer, the burden of the disease extends well beyond the physical challenges, often placing considerable financial strain on patients and their families," said Shreehas Tambe, CEO and managing director of Biocon Limited, in the release.1 "As our fifth oncology biosimilar to receive U.S. FDA approval, PEBRILZO strengthens our anti-cancer portfolio and advances our commitment to expanding access to high-quality, affordable biologic medicines."1

How does this fit into the HER2 biosimilar landscape?

Citing Surveillance, Epidemiology, and End Results data, Biocon noted that about 320,000 women in the United States are expected to be diagnosed with breast cancer in 2026, and about 20% of those cases are expected to be HER2 positive.1

Biocon's other US oncology biosimilars include trastuzumab-dkst (Ogivri), bevacizumab-nwgd (Jobevne), pegfilgrastim-jmdb (Fulphila), and denosumab-kyqq (Aukelso).1

ONN previously reported on the FDA's acceptance of the biologics license application for HLX11, the pertuzumab biosimilar that became pertuzumab-dpzb, and on that agent's approval in multiple breast cancer settings.3,4

What are the key takeaways for oncology nurses?

  • Pertuzumab-qcay is FDA approved but not expected to be available in the United States until the third quarter of 2028 at the earliest.1
  • When it launches, the indications, combination partners, and boxed warning match the reference product, so existing pertuzumab protocols for cardiac monitoring and infusion observation apply.1
  • LVEF assessment before and at regular intervals during treatment remains standard, along with teaching patients to report symptoms of heart failure.1
  • Pregnancy testing and contraception counseling remain part of pretreatment education because of the embryo-fetal toxicity warning.1
  • Biosimilar transitions can raise questions about cost and equivalence; nurses can explain that FDA-approved biosimilars have no clinically meaningful differences from the reference product.1,2

References

  1. Biocon gets U.S. FDA approval for Pebrilzo (pertuzumab-qcay) injection, a biosimilar to Perjeta, expanding its oncology portfolio. News release. Biocon Biologics. November 16, 2026. Accessed November 16, 2026. https://www.businesswire.com/news/home/20261116435734/en/Biocon-Gets-U.S.-FDA-Approval-for-Pebrilzo-pertuzumab-qcay-Injection-a-Biosimilar-to-Perjeta-Expanding-Its-Oncology-Portfolio
  2. FDA approves first interchangeable biosimilar to Perjeta to treat certain types of breast cancer. US Food and Drug Administration. November 2025. Accessed November 16, 2026. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-interchangeable-biosimilar-perjeta-treat-certain-types-breast-cancer
  3. Hoyt B. FDA approves pertuzumab biosimilar in breast cancer indications. Oncology Nursing News. November 13, 2025. Accessed November 16, 2026. https://www.oncnursingnews.com/view/fda-approves-pertuzumab-biosimilar-in-breast-cancer-indications
  4. Ryan C. Pertuzumab biosimilar BLA for HER2+ breast cancer accepted by FDA. Oncology Nursing News. February 7, 2025. Accessed November 16, 2026. https://www.oncnursingnews.com/view/pertuzumab-biosimilar-bla-for-her2-breast-cancer-accepted-by-fda

Related to this article